Astarte Medical, a Yardley, Pa.-based precision medicine company using software and predictive analytics to improve preterm infant outcomes, closed an additional $3.5m in financing.
The backers were not disclosed.
The company intends to use the funds to:
– accelerate hiring and ramp its sales and marketing efforts for its first two solutions, NICUtrition Analytics and NICUtrition Guidance,
– develop a regulatory strategy in support of a 2020 MAGI trial, the development of a health disparities platform, and
– explore and isolate novel therapeutic and diagnostic candidates.
Led by Tracy Warren, CEO and Co-Founder, Astarte Medical is a precision medicine company using software and predictive analytics to improve outcomes during the first 1,000 days of life, with an initial focus on preterm infants. NICUtrition supports feeding protocols, practice and decision-making in the neonatal ICU with a suite of digital tools and diagnostics designed to standardize feeding, optimize nutrition and quantify gut health.
The company plans to grow its team by 300% in 2020, adding in-house sales and marketing staff, as well as client support functions to assist early adopters. In addition, Astarte plans to expand its in-house engineering and data science teams to support continued product development.